Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients.

The prevalent renal transplant population presents an opportunity to observe the adaptive changes in the alloimmune response over time, but such studies have been limited by uncertainties in the conventional biopsy diagnosis of T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR). To circumvent these limitations, we used microarrays and conventional methods to investigate rejection in 703 unselected biopsies taken 3 days to 35 years post-transplant from North American and European centers. Using conventional methods, we diagnosed rejection in 205 biopsy specimens (28%): 67 pure TCMR, 110 pure ABMR, and 28 mixed (89 designated borderline). Using microarrays, we diagnosed rejection in 228 biopsy specimens (32%): 76 pure TCMR, 124 pure ABMR, and 28 mixed (no borderline). Molecular assessment confirmed most conventional diagnoses (agreement was 90% for TCMR and 83% for ABMR) but revealed some errors, particularly in mixed rejection, and improved prediction of failure. ABMR was strongly associated with increased graft loss, but TCMR was not. ABMR became common in biopsy specimens obtained >1 year post-transplant and continued to appear in all subsequent intervals. TCMR was common early but progressively disappeared over time. In 108 biopsy specimens obtained 10.2-35 years post-transplant, TCMR defined by molecular and conventional features was never observed. We conclude that the main cause of kidney transplant failure is ABMR, which can present even decades after transplantation. In contrast, TCMR disappears by 10 years post-transplant, implying that a state of partial adaptive tolerance emerges over time in the kidney transplant population.

[1]  P. Nickerson,et al.  Begin at the Beginning to Prevent the End. , 2015, Journal of the American Society of Nephrology.

[2]  D. Rush,et al.  Banff 2013 Meeting Report: Inclusion of C4d‐Negative Antibody‐Mediated Rejection and Antibody‐Associated Arterial Lesions , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  A. Matas,et al.  Microarray Diagnosis of Antibody‐Mediated Rejection in Kidney Transplant Biopsies: An International Prospective Study (INTERCOM) , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  A. Sánchez‐Fueyo Tolerance profiles and immunosuppression , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  D. Roelen,et al.  Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients , 2013, Hepatology.

[6]  A. Matas,et al.  Potential Impact of Microarray Diagnosis of T Cell–Mediated Rejection in Kidney Transplants: The INTERCOM Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[8]  K. Famulski,et al.  Molecular Diagnosis of Antibody‐Mediated Rejection in Human Kidney Transplants , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  K. Famulski,et al.  Molecular Diagnosis of T Cell‐Mediated Rejection in Human Kidney Transplant Biopsies , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  X. Jouven,et al.  Antibody-mediated vascular rejection of kidney allografts: a population-based study , 2013, The Lancet.

[11]  A. Sánchez‐Fueyo,et al.  A Need for Biomarkers of Operational Tolerance in Liver and Kidney Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  G. Jhangri,et al.  A New Diagnostic Algorithm for Antibody‐Mediated Microcirculation Inflammation in Kidney Transplants , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[14]  R. Waldherr,et al.  Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. , 2012, Journal of the American Society of Nephrology : JASN.

[15]  T. Reimer,et al.  The 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer , 2012, Breast Care.

[16]  D. Swinkels,et al.  Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. , 2012, The Journal of clinical investigation.

[17]  R. Colvin,et al.  Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. , 2011, Kidney international.

[18]  G. Klintmalm,et al.  High Mean Fluorescence Intensity Donor‐Specific Anti‐HLA Antibodies Associated With Chronic Rejection Postliver Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  A. Huang,et al.  Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization , 2011, BMC Cancer.

[20]  Tieliu Shi,et al.  A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data , 2010, The Pharmacogenomics Journal.

[21]  D. Rush,et al.  Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure , 2010, Transplantation.

[22]  S. Varughese,et al.  IL2 BLOCKER INDUCTION IN LIVING RELATED RENAL TRANSPLANTATION: 593 , 2010 .

[23]  Graham M Lord,et al.  Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. , 2010, The Journal of clinical investigation.

[24]  M. Suthanthiran,et al.  Identification of a B cell signature associated with renal transplant tolerance in humans. , 2010, The Journal of clinical investigation.

[25]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  L. Rostaing,et al.  A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[28]  P. Halloran,et al.  De Novo Donor‐Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft Failure , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  P. Halloran,et al.  Antibody‐Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  M. Stegall,et al.  Identifying Specific Causes of Kidney Allograft Loss , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  P. Parrilla,et al.  Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. , 2008, The Journal of clinical investigation.

[32]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[33]  G S Jhangri,et al.  Microarray Analysis of Rejection in Human Kidney Transplants Using Pathogenesis‐Based Transcript Sets , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  R. Colvin,et al.  Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’) , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  J. Davis Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[36]  V. Dharnidharka Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[37]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[38]  P. Halloran,et al.  Assessing Long‐Term Nephron Loss: Is It Time to Kick the CAN Grading System? , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  S. Cramer,et al.  International variation in histologic grading is large and persistent feedback does not improve reproducibility. , 2004, The American journal of surgical pathology.

[40]  N Taub,et al.  International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. , 2001, Kidney international.

[41]  A. Nagler,et al.  INCREASED IMPACT OF ACUTE REJECTION ON CHRONIC ALLOGRAFT FAILURE IN RECENT ERA , 2000, Transplantation.

[42]  M. Pescovitz,et al.  Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation , 1998 .

[43]  B. Iványi,et al.  Tubulitis in primary vascular and glomerular renal disease. , 1995, Pathology, research and practice.

[44]  W. Payne,et al.  THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2 , 1994, Transplantation.

[45]  G. Riethmüller,et al.  Vascular deposition of complement‐split products in kidney allografts with cell‐mediated rejection , 1991, Clinical and experimental immunology.

[46]  ohn,et al.  INTERLEUKIN-2 – RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 2017 .

[47]  B. Kasiske,et al.  US Renal Data System 2013 Annual Data Report. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  Nate Silver,et al.  The signal and the noise : why so many predictions fail but some don't , 2012 .

[49]  J. Sellarésa,et al.  Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence , 2011 .

[50]  M. Guba,et al.  Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation , 2018 .

[51]  D. Scholtens,et al.  Analysis of Differential Gene Expression Studies , 2005 .

[52]  J. Ayanian,et al.  Costimulation Blockade with Belatacept in Renal Transplantation , 2005 .

[53]  P. Halloran,et al.  The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. , 1990, Transplantation.